Sort   by:  
 Page size 
UnknownReal-world experience with obeticholic acid in patients with primary biliary cholangitis.

Background & aims

Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions.

Metho...

S-EPMC7930359 | biostudies-literature
UnknownPredictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.

Background & aims

Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-respon...
S-EPMC9804305 | biostudies-literature
UnknownLong-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world.

Background & aims

Several studies have assessed the short-term effectiveness and safety of obeticholic acid (OCA) in the real-world setting. We aimed to extend knowledge on the real-world effectiveness and safety of OCA treatment by expanding sample size and follow-up, and by exploring chang...
S-EPMC12276448 | biostudies-literature
Sort   by:  
 Page size